Today: 10 June 2026
Marvell (MRVL) stock drops 2% into year-end close as chip trade cools — what’s next
1 January 2026
2 mins read

Marvell (MRVL) stock drops 2% into year-end close as chip trade cools — what’s next

NEW YORK, December 31, 2025, 21:09 ET — Market closed

Marvell Technology (MRVL.O) fell $1.78, or about 2.1%, to $84.98 on Wednesday. Trading volume was about 7.2 million shares.

The decline came as Wall Street ended 2025’s final session lower in holiday-thin trade, with the Nasdaq down 0.76% and the S&P 500 off 0.74%, Reuters reported. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking when liquidity was low. Reuters

The year-end drift matters because the market’s gains have been driven by the artificial intelligence trade, leaving investors sensitive to repositioning and rate expectations heading into 2026. Reuters said investors are watching the Federal Reserve’s path as economic data returns to a more normal cadence.

For Marvell, the core question is whether data-center demand can sustain growth in its custom chip and networking businesses as cloud customers scale AI workloads. CEO Matt Murphy said earlier this month Marvell expected roughly $10 billion in total revenue for its next fiscal year, including a 25% jump in data center revenue, and projected its custom chip business to grow 20%.

Murphy has also pushed deeper into photonics — using light rather than electrical signals to connect chips and memory — as hyperscalers seek faster, more power-efficient data-center links. Reuters reported Marvell’s $3.25 billion agreement to acquire Celestial AI added photonics fabric technology and intensified competition with peers such as Broadcom and Nvidia.

A Dec. 2 SEC filing said Marvell expects the Celestial transaction to close in the first quarter of calendar 2026, subject to customary closing conditions and regulatory approvals. The filing said the deal includes about $1.0 billion in cash and about 27.2 million shares of Marvell common stock at closing, with additional shares tied to revenue-based milestones.

Before the next session, U.S. stock markets will be closed on Thursday for New Year’s Day and reopen on Friday, Jan. 2, with regular trading hours, Barron’s reported.

Rate expectations remain a key swing factor for semiconductors, which often trade like growth stocks because much of their valuation rests on future earnings. Reuters reported this week the Fed’s next policy meeting is scheduled for Jan. 27-28 and investors were expecting no change in the benchmark rate.

The next high-profile macro checkpoint is the Institute for Supply Management’s Manufacturing PMI report for December, due at 10 a.m. ET on Monday, Jan. 5. The PMI is a monthly survey-based gauge of factory activity; readings below 50 signal contraction.

Marvell has not confirmed its next earnings date, but Zacks expects the company to report around March 4. On the chart, Marvell ends the year below its 50-day moving average (about $87.5), while remaining above its 200-day moving average (about $74), levels traders often use as short- and longer-term trend markers.

Marvell has traded between roughly $47 and $127 over the past 52 weeks, according to Investing.com, leaving the stock well off its high even after early-December deal optimism.

With holiday volumes fading, the next directional cue is likely to come from early January data and the next round of company guidance on data-center demand and deal execution.

Stock Market Today

  • Crude Oil Prices Surge Amid US-Iran Tensions and Supply Concerns
    June 10, 2026, 5:47 PM EDT. Crude oil prices climbed sharply as President Trump vowed further military strikes on Iran following a series of exchanges in the Strait of Hormuz. July WTI crude rose 2.07%, while gasoline futures gained 2.94%, driven by geopolitical risks that threaten to disrupt supply. The US conducted airstrikes on Iranian defenses after Iran targeted US military bases, escalating tensions. Despite a brief pullback on reassurance over commercial ship passages through the vital shipping lane, prices stayed elevated. Meanwhile, global oil demand worries persist with China's crude imports hitting an eight-year low. The US Department of Energy raised its 2026 domestic production forecast, adding downward pressure. Support for prices also comes from Ukrainian drone attacks on Russian oil infrastructure, coupled with Western sanctions constraining Russian exports. The International Energy Agency noted ongoing global inventory declines.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop